Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.42 million versus the consensus estimate of $11.96 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.